Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | BRS3 | P32247 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | F9 | P00740 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 5/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23270276 | 0.92 | GRIN1 (0.57) | GRIN1GRIN2BF10ALDH1A1BRS3 | |
| SCHEMBL1886254 | 0.89 | THRB (0.46) | GRIN1GRIN2BF10ALDH1A1BRS3 | |
| SCHEMBL9194512 | 0.85 | CYP1A2 (0.61) | GRIN1GRIN2BF10BRS3KMT2A | |
| SCHEMBL10436145 | 0.83 | CYP1A2 (0.62) | GRIN1GRIN2BF10BRS3KMT2A | |
| SCHEMBL13263598 | 0.81 | CYP1A2 (0.59) | GRIN1GRIN2BF10ALDH1A1BRS3 | |
| SCHEMBL2844229 | 0.81 | PDE10A (0.52) | F10ALDH1A1KMT2APDE10AKDM4E | |
| SCHEMBL1977861 | 0.80 | RAD52 (0.61) | GRIN1GRIN2BF10ALDH1A1BRS3 | |
| SCHEMBL10272594 | 0.78 | CYP1A2 (0.61) | GRIN1GRIN2BF10ALDH1A1BRS3 | |
| SCHEMBL2843323 | 0.77 | AAK1 (0.43) | GRIN1GRIN2BF10ALDH1A1F9 | |
| SCHEMBL12635909 | 0.77 | F10 (0.61) | GRIN1GRIN2BF10ALDH1A1BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | GRIN1 911/4885GRIN2B 237/4885F10 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.